Newsoara BioPharma Co., Ltd. (Newsoara) - China Regional Partnership
In 2019, Zenith entered into a licensing agreement with Newsoara to develop ZEN-3694 for the China, Hong Kong, Taiwan and Macau markets. Newsoara owns 100% of the development and commercialization rights for ZEN-3694 in these markets and is responsible for all associated costs. In exchange for these rights, Zenith received an upfront payment and is eligible for development and commercial milestone payments and royalties. Zenith and Newsoara are currently collaborating to develop ZEN-3694 + enzalutamide in combination to treat metastatic castration resistant prostate cancer (mCRPC) in an ongoing China/USA Phase 2b randomized trial. More information can be found HERE.
National Cancer Institute (NCI) Clinical Research and Development Collaboration
In 2020, Zenith and NCI executed a cooperative and research collaboration agreement to develop ZEN-3694 for multiple oncology indications with different targeted combination agents. The collaboration will benefit from NCI’s extensive clinical development and regulatory infrastructure and most of the costs associated with the collaboration trials will be funded by NCI. Through this collaboration, ZEN-3694 is being evaluated in 10 clinical trials for safety and efficacy in multiple oncology indications with significant unmet need. More information can be found HERE.
University of California San Francisco / Merck Collaboration – mCRPC
UCSF is collaborating with Zenith and Merck to test the combination of ZEN-3694 + Merck’s immune checkpoint inhibitor, pembrolizumab, in metastatic castration-resistant prostate cancer patients who are androgen receptor pathway independent. This Phase 2 clinical trial led by Dr. Rahul Aggarwal at UCSF is evaluating the triple combination of ZEN-3694, pembrolizumab and Pfizer’s enzalutamide. Additional information on this clinical trial can be accessed HERE.
Memorial Sloan Kettering Cancer Center – Squamous Lung Carcinoma
MSKCC is collaborating with Zenith to evaluate ZEN-3694 in patients with NSD3 amplified squamous lung cancer. This Phase 2 clinical trial led by Dr. Paul Paik at MSKCC is evaluating the efficacy of ZEN-3694 as monotherapy in patients with NSD3 amplified squamous lung cancer. Additional information on this clinical trial can be accessed HERE.
University of Pittsburgh Medical Center – Hillman Cancer Center – Ovarian Cancer
UPMC is collaborating with Zenith to evaluate ZEN-3694 in combination with PARP inhibitor talazoparib in patients with recurrent ovarian cancer. This Phase 2 clinical trial led by Dr Alexander Olawaiye will evaluate the efficacy and safety of the combination. Additional information on this clinical trial can be accessed HERE.
Partnerships Contact
Sanjay Lakhotia, Ph.D., MBA
Chief Business Officer
E: info@zenithepigenetics.com
T: 1 (587) 390-7865
